11:52 AM EST - Ventripoint Diagnostics Ltd. : Announced that its Partner, Ma’anshan YuTian Medical Technology Co. Ltd, has received CFDA approval and a Certificate of Production (CoP) from the FDA in the People’s Republic of China for the VMS (QAS-R in China) system to be clinically used to analyze the right ventricle (RV) of the heart. Ventripoint Diagnostics Ltd.
shares V.VPT are trading up $0.015 at $0.22.
